The AspireSR device automates the magnet stimulation by sensing heart rate changes that are correlated with the patient’s seizure activity.
The generator then provides stimulation of the vagus nerve in response to the seizure.
Cyberonics has developed VNS Therapy System, which is the US Food and Drug Administration approved for the treatment of refractory epilepsy and treatment-resistant depression.
The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve.
Ghent University Epilepsy Group in Ghent, Belgium professor Paul Boon said the design is consistent with existing VNS devices, and the procedure was conducted in the usual manner, but the ability of the device to sense changes correlated with a seizure and induce responsive stimulation of the vagus nerve is unique.
Cyberonics president and CEO Dan Moore said they look forward to completing the enrollment of clinical trial, E-36.
